Taldefgrobep alfa
Modify Date: 2025-08-26 11:41:39
Taldefgrobep alfa structure
|
Common Name | Taldefgrobep alfa | ||
|---|---|---|---|---|
| CAS Number | 1580555-26-5 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Taldefgrobep alfaTaldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2]. |
| Name | Taldefgrobep alfa |
|---|
| Description | Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Myostatin[1] |
| In Vivo | Taldefgrobep alfa (2 mg/kg; iv or sc; single dose) 静脉注射小鼠后具有较快的血浆清除率，而皮下注射可使其被缓慢吸收 (Tmax=24 h)，Cmax 为 15.4 mg/mL，生物利用度 (F) 为84%[1]。 |
| References |
[2]. Straus M. 2023 Pipeline Report: Testing the Limits[J]. Pharmaceutical Executive, 2022, 42(12). |
| No Any Chemical & Physical Properties |